Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Morphosys Ag ADR (NQ: MOR ) 18.96 UNCHANGED Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Morphosys Ag ADR < Previous 1 2 3 4 Next > Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting August 27, 2024 Via ACCESSWIRE SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders July 17, 2024 From Halper Sadeh LLC Via GlobeNewswire MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market July 12, 2024 From MorphoSys AG Via Business Wire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DM, SHCR, MOR, ALE on Behalf of Shareholders July 08, 2024 From Halper Sadeh LLC Via GlobeNewswire Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024 March 07, 2024 Via ACCESSWIRE MorphoSys AG (NASDAQ: MOR) Near the Top of Equities by Percentage Gain on 2/5 February 05, 2024 Via Investor Brand Network SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders June 29, 2024 From Halper Sadeh LLC Via GlobeNewswire MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders June 20, 2024 From Halper Sadeh LLC Via Business Wire MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders June 20, 2024 From MorphoSys AG Via Business Wire Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders June 19, 2024 Via ACCESSWIRE MorphoSys AG (NASDAQ: MOR) Leading the Way in Monday Trading Based on Percentage Gain December 11, 2023 Via Investor Brand Network Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023 November 09, 2023 Via ACCESSWIRE MorphoSys AG Reports First Quarter 2024 Financial Results April 29, 2024 From MorphoSys AG Via Business Wire MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting April 24, 2024 Via ACCESSWIRE MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis April 11, 2024 From MorphoSys AG Via Business Wire MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis April 11, 2024 Via ACCESSWIRE MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act March 21, 2024 Via ACCESSWIRE MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update March 13, 2024 From MorphoSys AG Via Business Wire MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value February 05, 2024 Via ACCESSWIRE MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability January 29, 2024 Via ACCESSWIRE MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 07, 2024 Via ACCESSWIRE MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study December 10, 2023 From MorphoSys AG Via Business Wire Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction November 20, 2023 Via ACCESSWIRE MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction November 20, 2023 From MorphoSys AG Via Business Wire MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results November 15, 2023 From MorphoSys AG Via Business Wire MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting November 02, 2023 Via ACCESSWIRE MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023 October 25, 2023 Via ACCESSWIRE MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer September 12, 2023 Via ACCESSWIRE MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results August 09, 2023 From MorphoSys AG Via Business Wire MorphoSys AG Reports First Quarter 2023 Financial Results May 03, 2023 From MorphoSys AG Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.